Literature DB >> 17109345

A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes.

Jonas Soderholm1, Matti Sallberg.   

Abstract

The hepatitis C virus nonstructural (NS) 3/4A protease sequence is highly conserved for reasons not fully understood. We determined the protease activity in 181 NS3/4A gene products in which each protease residue was replaced by alanine or glycine. Unexpectedly, most (87%) protease residues could be replaced and protease activity would be retained. Using these data, we were able to identify a human leukocyte antigen A2-restricted epitope in which substitutions at 5 of 9 residues destroyed the protease. The NS3 protease shows an unexpectedly high plasticity, and it is therefore important to identify target sequences in which the appearance of mutations is restricted by viral fitness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109345     DOI: 10.1086/509513

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.

Authors:  Louai Labanieh; Robbie G Majzner; Dorota Klysz; Elena Sotillo; Chris J Fisher; José G Vilches-Moure; Kaithlen Zen B Pacheco; Meena Malipatlolla; Peng Xu; Jessica H Hui; Tara Murty; Johanna Theruvath; Nishant Mehta; Sean A Yamada-Hunter; Evan W Weber; Sabine Heitzeneder; Kevin R Parker; Ansuman T Satpathy; Howard Y Chang; Michael Z Lin; Jennifer R Cochran; Crystal L Mackall
Journal:  Cell       Date:  2022-04-27       Impact factor: 66.850

2.  Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  PLoS Pathog       Date:  2015-09-30       Impact factor: 6.823

3.  Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; M Meleah Mathahs; Warren N Schmidt; Thomas M Kaufman; Jack T Stapleton
Journal:  PLoS Pathog       Date:  2017-02-24       Impact factor: 6.823

4.  Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Authors:  G Ahlén; E Derk; M Weiland; J Jiao; N Rahbin; S Aleman; D L Peterson; K Pokrovskaja; D Grandér; L Frelin; M Sällberg
Journal:  Gut       Date:  2008-08-08       Impact factor: 23.059

5.  A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Authors:  Anne Fournillier; Lars Frelin; Emilie Jacquier; Gustaf Ahlén; Anette Brass; Estelle Gerossier; Fredrik Holmström; Kate E Broderick; Niranjan Y Sardesai; Jean-Yves Bonnefoy; Geneviève Inchauspé; Matti Sällberg
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.